from Epigenomics AG (isin : DE000A0BVT96)
EQS-Adhoc: Epigenomics AG: Changes in the Management
EQS-Ad-hoc: Epigenomics AG / Key word(s): Personnel
Epigenomics AG: Changes in the Management
12-Apr-2023 / 19:56 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Epigenomics AG: Changes in the Management
Berlin, Germany, April 12, 2023 – In connection with its revised strategy, Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY) announces changes to its Executive Board. The Chief Executive Officer of Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the "Company"), Mr. Greg Hamilton, is resigning from the Company and the Executive Board effective June 30, 2023.
Discussions will also be initiated with the other members of the Executive Board about the future composition of the Executive Board with regard to the restructuring of the company.
Contact:
Company
Epigenomics AG, Geneststrasse 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: contact@epigenomics.com
Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com
Note on forward-looking statements
This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.
End of Inside Information
12-Apr-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Epigenomics AG |
| Geneststraße 5 | |
| 10829 Berlin | |
| Germany | |
| Phone: | +49 30 24345-0 |
| Fax: | +49 30 24345-555 |
| E-mail: | ir@epigenomics.com |
| Internet: | www.epigenomics.com |
| ISIN: | DE000A32VN83 |
| WKN: | A32VN8 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1606315 |
| End of Announcement | EQS News Service |
1606315 12-Apr-2023 CET/CEST